Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681928 | 1.00 | KEAP1 (0.49) | KEAP1NFE2L2ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL30682029 | 0.86 | ALDH1A1 (0.50) | KEAP1NFE2L2ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL2310035 | 0.86 | ALDH1A1 (0.50) | KEAP1NFE2L2ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL8574083 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2TP53TSHRCASP1 | |
| SCHEMBL26617646 | 0.83 | KEAP1 (0.54) | KEAP1NFE2L2ALDH1A1ALOX5MEN1 | |
| SCHEMBL5203185 | 0.83 | ALDH1A1 (0.71) | KEAP1NFE2L2ALDH1A1KDM4EMEN1 | |
| SCHEMBL1284870 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2TP53TSHRCASP1 | |
| SCHEMBL22743009 | 0.83 | KEAP1 (0.46) | KEAP1NFE2L2ALDH1A1KDM4EGPR35 | |
| SCHEMBL18987952 | 0.80 | ALDH1A1 (0.46) | KEAP1NFE2L2ALDH1A1KDM4EMEN1 | |
| SCHEMBL27699425 | 0.80 | FABP3 (0.51) | ALDH1A1SMN1; SMN2TP53TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1668009-A1 | HCV INHIBITORS AND METHODS OF USING THEM | Rigel Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005121138-A2 | HETEROTRICYCLIC COMPOUNDS FOR USE AS HCV INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005030774-A1 | HCV INHIBITORS AND METHODS OF USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | KEAP1 78/4885NFE2L2 834/4885ALDH1A1 874/4885 |
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | KEAP1 78/4885NFE2L2 834/4885ALDH1A1 874/4885 |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | HAVCR2, PYGL, HCCS | KEAP1 440/4885NFE2L2 1392/4885ALDH1A1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.